BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.
BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.